IPO Boutique

Concert Pharmaceuticals, Inc. IPO Advisory

Share this IPO Profile:

Smart Search
Company begins with...
Company contains...

For IPO Boutique's "scale of 1 to 5" BUY rating on Concert Pharmaceuticals, Inc., and our comprehensive analysis, click "Buy Market Research".
Company
Symbol
Price Range
Issue Price
Open
Shares
Trade Date
Concert Pharmaceuticals, Inc.CNCE -
NASDAQ
$12.00-$14.00 $14.00 $15.756 million2/13/2014
UBS Investment Bank, Wells Fargo Securities
Co-Manager(s):
JMP Securities, Roth Capital Partners
Health Care
Filing(s):

Filed 2014-01-13



Concert Pharmaceuticals, Inc. Quote & Chart - Click for current quote - CNCE

About Concert Pharmaceuticals, Inc. (adapted from Concert Pharmaceuticals, Inc. prospectus):
They are a clinical stage biopharmaceutical company applying our extensive knowledge of deuterium chemistry to discover and develop novel small molecule drugs.

This description is adapted from Concert CNCE prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.



IPO Boutique aggregates information on public companies and private companies, such as Concert CNCE "CNCE" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.

Used our Comprehensive Single Promo Advisory and want more?
We also offer a monthly or annual subscription






© 2005 - 2024 IPO Boutique. All Rights Reserved